Tirzepatide, also known as Mounjaro®, is a GLP1/GIP agonist. Other medications such as semaglutide (Wegovy®), liraglutide (Saxenda®), are known as GLP-1 agonists. Both types of drug work in the same way and mimic gut hormones released by the body after eating, telling the brain you are full and slowing down the time it takes the stomach to empty.
23 June 2025 will see the beginning of access to the drug tirzepatide (Mounjaro®) for the management of obesity in primary care settings to eligible patients.
Tirzepatide (Mounjaro®) will not be accessible to everyone who wishes to use it. People with the highest health risks and who meet the clinical criteria will be
prioritised.
From 23 June 2025, people who meet the qualifying criteria (a BMI of at least 40 and four of the five stated weight related comorbidities), will be able to gain access to the drug via primary care, if both patient and clinician agree it is the most appropriate treatment option.
Full qualifying criteria is a BMI (Body Mass Index) of 40 plus and four or more of the following diagnosed health conditions:
- type 2 diabetes
- high blood pressure
- heart disease
- obstructive sleep apnoea
- abnormal blood fats (dyslipidaemia)
Access to tirzepatide (Mounjaro®) via the NHS is for those at greatest risk of ill health, or who are experiencing severe ill health due to living with obesity. Access to the drug must be accompanied by wraparound care which will include support for people to make dietary changes and to increase physical activity.
For more infromation please click here : Mounjaro (Tirzepatide) - NHS Cheshire and Merseyside